BioStock: Shift to regenerative medicine increases growth prospects for PHI
With a sharp focus on expanding its market to regenerative medicine, medtech company PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter. BioStock talked to the company CEO, Patrik Eschricht, for an operational overview and to learn about the behind-the-scenes developments right now.
Read the full interview with Patrik Eschricht at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/